论文部分内容阅读
组蛋白的乙酰化和去乙酰化是基因表达过程中重要的调控方式,是转录过程中的关键修饰。近年来研究表明组蛋白去乙酰化酶6(HDAC6)通过去除组蛋白的乙酰基和其他转录调控参与肿瘤发生和进展。在细胞分裂周期中不恰当的去乙酰化及从胞质到胞核的重新分布,都可能引起转录抑制,基因表达异常,诱发肿瘤。HDAC6的抑制剂和其他抗癌药物联合应用将有可能找到一条治疗肿瘤新的途径。本文综述了HDAC6在肿瘤发生发展过程中的最新进展。
Acetylation and deacetylation of histones are important regulators of gene expression and are key modifications in transcription. Recent studies have shown that histone deacetylase 6 (HDAC6) is involved in tumorigenesis and progression by removing histone acetyl and other transcriptional regulators. Inadequate deacetylation during cell division cycles and redistribution from the cytoplasm to the nucleus may cause transcriptional repression, abnormal gene expression, and tumor induction. The combination of HDAC6 inhibitors and other anticancer drugs will make it possible to find a new way to treat tumors. This review summarizes the latest progress of HDAC6 in tumorigenesis.